{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:43Z","timestamp":1740144223219,"version":"3.37.3"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Existing evidence on the difference in the incidence of tumor lysis syndrome (TLS) in Chronic Lymphocytic Leukemia (CLL) patients receiving novel therapies versus patients receiving conventional therapies is limited and inconclusive. The aims of this planned systematic review and meta-analysis are therefore<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will conduct a systematic review and meta-analysis. Several electronic databases will be searched using predefined search terms to identify relevant studies. Eligible studies should report findings on the incidence of TLS in CLL patients. Primary observational studies with cross-sectional or prospective research design, case-control studies, and studies with experimental designs will be included. Study quality will be evaluated by 2 reviewers using the statistical methodology and categories described in the Cochrane Collaboration Handbook and preferred reporting items for systematic reviews and meta-analyses and other applicable guidelines. The meta-analysis will be performed and conducted using applicable standard statistical software like comprehensive meta-analysis and STATA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This review and meta-analysis will be among the first to systematically explore and integrate the evidence available on the comparison between the incidences of TLS in CLL patients treated with novel agents versus conventional agents. By gathering and summarizing information about the risk of TLS in this patient population, the findings from this review will provide insights for future research directions and more understanding of the difference of TLS incidence between novel treatments and conventional treatment and suggest prophylactic measures for such cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Systematic review registration:<\/jats:title>\n            <jats:p>The protocol has been registered at the International Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD42020166770).<\/jats:p>\n            <jats:p>The protocol was registered with the Hamad medical corporation, Medical research Center registry under a unique reference number (MRC-01-20-709).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023632","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T21:23:30Z","timestamp":1608240210000},"page":"e23632","source":"Crossref","is-referenced-by-count":2,"title":["Tumor lysis syndrome in chronic lymphocytic leukemia: conventional treatment versus novel agents"],"prefix":"10.1097","volume":"99","author":[{"given":"Nancy","family":"Kassem","sequence":"first","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Ghazy","sequence":"additional","affiliation":[{"name":"Bariatric Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abu-Tineh","sequence":"additional","affiliation":[{"name":"Medical Oncology\/Hematology Department, National Centre for Cancer Care and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-7987","authenticated-orcid":false,"given":"Nabil E.","family":"Omar","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-4119","authenticated-orcid":false,"given":"Abdulqadir J.","family":"Nashwan","sequence":"additional","affiliation":[{"name":"Nursing Department, Hazm Mebaireek General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem","family":"Chandra","sequence":"additional","affiliation":[{"name":"Medical Research Center Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rola","family":"Ghasoub","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama S.","family":"AbuTabar","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Cleveland Clinic Abu Dhabi & MSc Experimental and Translational Therapeutics Candidate, University of Oxford-Kellogg College."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-8076","authenticated-orcid":false,"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Medical Oncology\/Hematology Department, National Centre for Cancer Care and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"R1-20240318","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","article-title":"Biology of chronic lymphocytic leukemia in different microenvironments. clinical and therapeutic implications","volume":"27","author":"Herishanu","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"R2-20240318","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/17474086.2016.1127156","article-title":"Tumor lysis syndrome: Review of pathogenesis, risk factors and management of a medical emergency","volume":"9","author":"Criscuolo","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"R3-20240318","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"R4-20240318","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000320581","article-title":"Acute tumor lysis syndrome \u2013 a rare complication in the treatment of solid tumors","volume":"33","author":"Coiffier","year":"2010","journal-title":"Onkologie"},{"key":"R5-20240318","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"key":"R6-20240318","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20240318","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta- analysis of the randomized trials","volume":"91","author":"Richards","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R8-20240318","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood.V75.7.1414.1414","article-title":"Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients","volume":"75","author":"Binet","year":"1990","journal-title":"Blood"},{"key":"R9-20240318","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"R10-20240318","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/leu.2017.246","article-title":"Early, risk-Adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group","volume":"31","author":"Hoechstetter","year":"2017","journal-title":"Leukemia"},{"key":"R11-20240318","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"key":"R12-20240318","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"R13-20240318","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"R14-20240318","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"R15-20240318","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.clml.2018.08.007","article-title":"Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"18","author":"Barrientos","year":"2018","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"R16-20240318","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"R17-20240318","first-page":"339","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R18-20240318","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"J Am Med Assoc"},{"key":"R19-20240318","first-page":"349","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: elaboration and explanation","author":"Shamseer","year":"2015","journal-title":"BMJ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T11:10:50Z","timestamp":1710760250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023632"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":19,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023632","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}